American Institute for Plastic Surgery is Using Artefill to Fight Patient Wrinkles
* Reuters is not responsible for the content in this press release.
American Institute for Plastic Surgery is Using Artefill to Fight Patient
Wrinkles
Dermal Filler Offers Greatest Value and Longest Lasting Results
PLANO, Texas, Sept. 1 /PRNewswire/ -- American Institute for Plastic Surgery,
one of the leading plastic surgery centers in the metro-Dallas area, is using
Artefill to help patients fight wrinkles for good.
Artefill is the first and only FDA-approved microsphere-enhanced collagen
filler for the correction of smile lines and is one of the cutting edge
products co-founders Dr. Peter Raphael and Dr. Scott Harris have been using to
treat patients who want a dermal filler that lasts more than a few months.
Dr. Raphael commented, "As surgeons, we are drawn to products that offer
long-term solutions and Artefill fills this need for our patients that want a
lasting solution for wrinkle correction. We find Artefill offers enormous
value as it lasts longer than any other filler on the market today."
Artefill is a simple, in-office procedure that takes approximately fifteen
minutes to complete. A patient is injected with the product similar to other
dermal fillers with the key difference being its lasting effect. The unique
microspheres in Artefill are not absorbed by the body and therefore provide
the support the skin needs for long lasting natural feeling results. This is
different from temporary dermal fillers that are made of different kinds of
natural or synthetic materials that are completely absorbed by the body over
time and require repeat injections to maintain wrinkle correction. A skin test
is required prior to treatment or approximately four (4) weeks ahead of time,
to ensure a patient is not allergic to the collagen or anesthetic in Artefill.
One of Dr. Raphael's patients said, "I have tried the other fillers but I
never felt fully satisfied. It was also tiring coming back into the office
every few months for a touch up. Since having Artefill, I look and feel
younger. It was worth paying a little extra money upfront for a product that
will actually last."
Artefill is only offered by a select group of physicians in Texas and is not
available at all physician offices. Drs. Raphael and Harris are a few of the
company trained and select few company sponsored physicians who have the
skills and experience needed to administer the product.
About Artefill
Artefill is the first and only FDA-approved microsphere-enhanced collagen
filler for the correction of nasolabial folds, better known as smile lines.
The safety and effectiveness of Artefill has been extensively studied over the
past eight years. Since Artefill was approved in 2006, over 10 thousand
patients have been treated successfully with very high satisfaction rates.
Suneva Medical, Inc., a medical technology company focused on developing,
manufacturing and commercializing novel, differentiated aesthetic products for
the dermatology, plastic and cosmetic surgery markets, markets and
manufactures Artefill. For more information visit
http://www.artefill.com/content/c/whatisartefill/overview.asp or
www.sunevamedical.com.
About American Institute for Plastic Surgery
Dr. Peter Raphael and Dr. Scott Harris are board-certified by the American
Board of Plastic Surgery and members of the American Society of Plastic
Surgeons. They co-founded The American Institute for Plastic Surgery, a 15,000
square-foot world-class facility that provides plastic surgery services to
thousands of patients from around the world. For more information visit
http://www.ai4ps.com/american-institute-for-plastic-surgery.nxg or call
972-543-2477.
ATTENTION MEDIA: To download Artefill patient before and after pictures visit
http://www.artefill.com/content/c/beforeandafter/overview.asp.
Contact:
Catherine Walker
972-543-2469
SOURCE American Institute for Plastic Surgery
Catherine Walker, +1-972-543-2469
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.



Follow Reuters